Um die volle Funktionalität der Webseite nutzen zu können, müssen Sie JavaScript in ihrem Browser aktivieren.

DAX23.163,39-0,63 %

Gold3.366,39-0,08 %

Öl (Brent)77,58+1,67 %

Dow Jones41.898,11-0,62 %

US Tech 10021.542,26-0,78 %

EUR/USD1,14835-0,01 %

Top 15 der gesamten Suchanfragen der letzten 7 Tage

Login

Cantargia Aktie

Aktie

ISIN: SE0006371126 WKN: A2JAZX Land Flagge SE

Schweden

Zur Watchlist hinzufügen Zum Portfolio hinzufügen

Zum Portfolio hinzufügen

0,1083

EUR

-1,46 %

-0,0016 EUR

Letzter Kurs 15:16:11 Lang & Schwarz

Cantargia Aktie kaufen

Geldkurs

15:16:11

0,0913

EUR

22.051 STK

Briefkurs

15:16:11

0,1252

EUR

22.051 STK

BEI SMARTBROKER+ HANDELN

Handeln über unsere
Partner-Broker

Brokerize

Neueste Nachrichten

Cantargia Signs SEK 50 Million Financing Facility Agreement, Extending Cash Runway Into 2026 and Providing Operating Flexibility to Drive Strategic Plans 17.06.25 · Accesswire · Cantargia
Cantargia’s Nadunolimab Aantibody Awarded US FDA Fast Track Designation 11.06.25 · Accesswire · Cantargia
Cantargia Publishes Promising Preclinical Results Highlighting CAN10's Potential to Inhibit Vascular Inflammation 19.05.25 · Accesswire · Cantargia
Bulletin from the Annual General Meeting in Cantargia AB 15.05.25 · Accesswire · Cantargia
Cantargia Publishes Interim Report for the First Quarter of 2025 13.05.25 · Accesswire · Cantargia
Cantargia Announces Successful Phase 1 Results: PK/PD Data of Subcutaneously Administered CAN10 Confirms Every 4-Week Dosing Choice in Phase 2 12.05.25 · Accesswire · Cantargia
Cantargia’s Announces Publication of Clinical Data Demonstrating Potential of Nadunolimab Plus Pembrolizumab in Solid Tumors 06.05.25 · Accesswire · Cantargia
Invitation to the Presentation of Cantargia's Interim Report for Q1 2025 29.04.25 · Accesswire · Cantargia
Cantargia Announces Selection of Treatment Resistant Atopic Dermatitis as Second Target Indication for CAN10 29.04.25 · Accesswire · Cantargia
Cantargia Announces the Publication of Preclinical Data Highlighting Nadunolimab's Potential to Counteract Tumor-Driven Systemic Immunosuppression 28.04.25 · Accesswire · Cantargia
Cantargia Presents Association Between Nadunolimab and Reduction of Chemotherapy Induced Peripheral Neuropathy (CIPN) at AACR 25.04.25 · Accesswire · Cantargia
Cantargia Presents Promising Preclinical Results on Anti-IL1RAP Antibody-Drug Conjugate (ADC) at a Major Cancer Conference 25.04.25 · Accesswire · Cantargia

1
2
3
…
4

Meistgelesen

7 Tage
30 Tage
12 Monate

Cantargia Signs SEK 50 Million Financing Facility Agreement, Extending Cash Runway Into 2026 and ... 112 Leser

Cantargia Signs SEK 50 Million Financing Facility Agreement, Extending Cash Runway Into 2026 and ... 112 Leser
Cantargia’s Nadunolimab Aantibody Awarded US FDA Fast Track Designation 108 Leser

First Patient Enrolled in Cantargia's Leukemia Study with nadunolimab 148 Leser
Cantargia’s Announces Publication of Clinical Data Demonstrating Potential of Nadunolimab Plus ... 128 Leser
Cantargia Publishes Full Year Report for 2024 120 Leser
Cantargia Publishes Promising Preclinical Results Highlighting CAN10's Potential to Inhibit ... 116 Leser
Cantargia Publishes Annual Report 2024 116 Leser
Notice of Annual General Meeting in Cantargia AB (publ) 116 Leser
Cantargia’s TRIFOUR Phase 2 Study Investigating Nadunolimab in Triple Negative Breast Cancer ... 116 Leser
Cantargia Signs SEK 50 Million Financing Facility Agreement, Extending Cash Runway Into 2026 and ... 112 Leser
Bulletin from the Annual General Meeting in Cantargia AB 112 Leser
Cantargia to Participate at Van Lanschot Kempen’s Life Sciences Conference 112 Leser